The combination of alpelisib and the MEK inhibitor trametinib is currently studied in a phase 1 trial in progressive refractory meningioma (NCT03631953) based on unpublished preclinical results that trametinib may induce apoptosis in meningioma cell lines. This evidence concerns the gene MAP2K7 and meningioma.